Occult primary, version 3.2014 Journal Article

  


Authors: Ettinger, D. S.; Handorf, C. R.; Agulnik, M.; Bowles, D. W.; Cates, J. M.; Cristea, M.; Dotan, E.; Eaton, K. D.; Fidias, P. M.; Gierada, D.; Weldon Gilcrease, G.; Godby, K.; Iyer, R.; Lenzi, R.; Phay, J.; Rashid, A.; Saltz, L.; Schwab, R. B.; Shulman, L. N.; Smerage, J. B.; Stevenson, M. M.; Varadhachary, G. R.; Zager, J. S.; Zhen, W.; Bergman, M. A.; Freedman-Cass, D. A.
Article Title: Occult primary, version 3.2014
Abstract: The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation. © National Comprehensive Cancer Network, Inc. 2014.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 12
Issue: 7
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2014-07-01
Start Page: 969
End Page: 974
Language: English
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84903965503&partnerID=40&md5=acf4b69a5063b2c4f3b54be7c98a1492
Notes: Export Date: 1 August 2014 -- Source: Scopus
MSK Authors
  1. Leonard B Saltz
    790 Saltz
Related MSK Work